Pfizer Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Pfizer Inc trades at $24.9 (market cap $142.14B), while Vanguard Total International Stock Index Fund ETF trades at $84.51. The key difference: Pfizer Inc pays a 6.9% dividend while Vanguard Total International Stock Index Fund ETF pays none, and Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| PFE | VXUS | |
|---|---|---|
Market Cap | $142.14B | — |
Volume | 29,869,932 | — |
Sector | Health | Sector/Thematic |
52-Week High | $28.56 | $87.06 |
52-Week Low | $23.29 | $68.24 |
Enterprise Value | $192.80B | — |
Dividend Yield | 6.9% | — |
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.
Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.
VXUS trades at $83.07, down 0.36% with a bearish technical signal from moving averages. The ETF provides diversified international exposure to over 8,700 non-U.S. stocks across developed and emerging markets. Recent institutional buying activity includes Greenwood Gearhart increasing its position by 45.8% in Q1 2026. Technical indicators show neutral oscillators but bearish momentum with support at $82 and resistance at $84.
The outlook remains cautious due to global economic uncertainty, though VXUS offers diversification benefits for U.S.-centric portfolios. Key risks include currency fluctuations and emerging market volatility. Analyst sentiment is mixed with some recommending international diversification while others caution about growth/inflation dynamics in global markets.
Trailing returns across standard periods
Latest headlines on both assets
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →